NCT06253494: Pembrolizumab, Lenvatinib and IL-15 Superagonist N-803 in Combination With HER2 Targeting Autologous Dendritic Cell (AdHER2DC) Vaccine in Participants With Advanced or Metastatic Endometrial Cancer
- State
- Under way
- Phase
- Phase 1 and Phase 2
- People
- 60 planned
- Started
- 14 May 2024
- Primary completion
- 31 Dec 2026
- Arms
- Arm 1
- Results
- None posted
- 12 Feb 2024: Trial registered
- 14 May 2024: Trial started